Uppsala, December 8, 2022. The pharmaceutical company Dicot announces that results from the latest study of the mechanism of action of LIB-01 have been selected to be presented at the European Society for Sexual Medicine's annual congress in February 2023.
The European Society for Sexual Medicine (ESSM) is the leading scientific society in sexual medicine and the annual congress in February brings together prominent researchers and clinicians from all over the world.
Dicot together with the partner Pelvipharm submitted an abstract with results from the latest study of the mechanism of action of LIB-01, i.e., how the drug works in the body to achieve the desired effect. The results show that the mechanism of action differs from today's potency drugs and that LIB-01 can thus represent a completely new generation of potency drugs.
The ESSM Scientific Council has now approved and selected Dicot's study results for presentation at the Annual Congress in Rotterdam in February 2023.
"For the second year in a row, ESSM handpicks our study results. That confirms the uniqueness of our drug candidate. The fact that our studies on the mechanism of action show that LIB-01 may come to represent a new generation of potency drugs, have a substantial news value in this medical field", says Elin Trampe, CEO at Dicot.
For further information, please contact:
Elin Trampe, CEO
Tel: +46 739 80 14 08
elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 60 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.